Resumption of Imatinib dosing to control metastatic Gastrointestinal Stromal Tumors (GIST) after failure of Imatinib and Sunitinib: Results of a randomised, placebo-controlled, phase 3 trial (RIGHT)

BACKGROUND: We conducted a prospective, randomised, double-blind trial to evaluate the efficacy of imatinib rechallenge in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) following objective progression of prior approved tyrosine kinase inhibitor (TKI) therapy. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Kang, Yoon-Koo, Ryu, Min-Hee, Yoo, Changhoon, Ryoo, Baek-Yeol, Kim, Hyun Jin, Lee, Jong Jin, Nam, Byung-Ho, Ramaiya, Nikhil, Jagannathan, Jyothi, Demetri, George D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4347867/
https://ncbi.nlm.nih.gov/pubmed/24140183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70453-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados